A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcade in Untreated Patients With Multiple Myeloma More Than 65 Years Old.

Trial Profile

A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcade in Untreated Patients With Multiple Myeloma More Than 65 Years Old.

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Bortezomib (Primary) ; Prednisone (Primary) ; Thalidomide (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 25 Jun 2017 Results validating the use of Serum-Free Light-Chains (sFLC) assay in patients being treated in GEM/PETHEMA clinical trials (GEM05menos65, GEM05MAS65, GEM2010MAS65 and GEM2012menos65), presented at the 22nd Congress of the European Haematology Association.
    • 25 Jun 2017 Results evaluating the factors associated with early death treated in two prospective trials (GEM05MAS65 and GEM2010MAS65), presented at the 22nd Congress of the European Haematology Association.
    • 23 Oct 2015 Results published in the Blood
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top